Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- (-) Safety monitoring and information (27)
- Committees and advisory bodies (384)
- Scheduling (national classification system) (166)
- Advertising (25)
- COVID-19 (11)
- Manufacturing (11)
- Clinical trials (6)
- Medicinal cannabis hub (6)
- Sunscreens (5)
- Compliance and enforcement (4)
- Fees and payments (4)
- Shortages and supply disruptions (4)
- Legislation (3)
- Import and export (2)
- Breast implant hub (1)
- Cosmetics (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
27 result(s) found, displaying 1 to 25
-
Meeting statementsCommunique from the 11th meeting of the Women's Health Products Working Group, 30 October 2025
-
Meeting statementsAdvisory Committee on Vaccines meeting statement 54
-
Meeting statementsMedical device reforms: Consumer Working Group meeting statement, Meeting 17, 22 August 2025
-
Meeting statementsCommunique from the 10th meeting of the WHPWG, 17 July 2025
-
Meeting statementsAdvisory Committee on Vaccines meeting statement 53
-
Meeting statementsCommunique from the 9th meeting of the WHPWG 27 March 2025
-
Corporate reportsThe report cards show the progress made by the TGA in the 3 strategies that make up the Action Plan for Medical Devices.
-
Meeting statementsCommunique from the 8th meeting of the WHPWG 30 October 2024
-
Meeting statementsAdvisory Committee on Vaccines meeting statement 52
-
Meeting statementsMeeting statement from the 16th Consumer Working Group meeting that took place on 25 March 2025.
-
Corporate reportsFind out about the seasonal influenza vaccines available for the 2025 southern hemisphere season.
-
Corporate reportsClarifies requirements for SAS and AP applications for healthcare practitioners to access Category 2, 3, 4 and/or 5 (i.e. Schedule 8) medicinal cannabis medicines for their patients under the age of 18 years (paediatric patients).
-
Meeting statementsAdvisory Committee on Vaccines meeting statement 49 for meeting held 2 October 2024
-
Meeting statementsMeeting statement from the 15th Consumer Working Group meeting that took place on 8 November 2024.
-
Scheduling decisions (final)This web publication constitutes a notice for the purposes of regulations 42ZCZS of the Therapeutic Goods Regulations 1990 (the Regulations).
-
Scheduling decisions (final)This web publication constitutes a notice for the purposes of regulations 42ZCZS and 42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations).
-
Corporate reportsMDSU provides practical advice and information about medical device safety.
-
Corporate reportsMandatory reporting of medical device adverse events by healthcare facilities to the TGA has now commenced, with a period of voluntary reporting in place from March 2025 until 20 March 2026.
-
TGA laboratory testing reportsIn consultation with the TGA, Edgewell has taken a precautionary approach and commenced a recall of all batches of these three products from the Australian market.
-
Corporate reportsThese guidelines apply to company-sponsored post-marketing surveillance studies of drug safety and toxicity
-
Corporate reportsInsights into therapeutic goods safety regulatory activity for our recalls program.
-
Corporate reportsThe TGA has published insights into recalls and GMP regulation for 2019-20.
-
Corporate reportsYou can help by sharing our messages on social media, your website and around your workplace.
-
TGA laboratory testing reportsTGA Laboratories has released a report detailing testing of alkyl nitrite products
-
Corporate reportsReporting medical device adverse incidents